Usefulness of Bezafibrate for Ovulation Induction in Clomiphene Citrate-Resistant Polycystic Ovary Syndrome Patients with Dyslipidemia: A Prospective Pilot Study of Seven Cases

作者：Hara Shuichiro; Takahashi Toshifumi^*; Amita Mitsuyoshi; Igarashi Hideki; Kurachi Hirohisa

来源：Gynecologic and Obstetric Investigation, 2010, 70(3): 166-172.

DOI：10.1159/000316265

• Polycystic ovary syndrome
• Clomiphene citrate resistance
• Insulin resistance
• Bezafibrate
• Dyslipidemia

Background: Dyslipidemia is commonly observed in polycystic ovary syndrome (PCOS) patients. Bezafibrate is a drug for dyslipidemia acting through peroxisome proliferator-activated receptors. We investigated the effects of bezafibrate for ovulation induction in patients with PCOS with dyslipidemia who were resistant to clomiphene citrate (CC). Methods: This was a prospective pilot study. Seven infertile, CC-resistant, PCOS patients with dyslipidemia were enrolled in this study. The participants received bezafibrate at 400 mg/day from day 1 of menses and CC at 100 mg/day from day 5 of menses simultaneously until one follicle measuring at least 18 mm in diameter was found by transvaginal ultrasound. The main outcome was ovulation rate. Results: Five of 7 patients successfully ovulated. The mean number of days of menses until the follicle reached 18 mm in diameter was 16 8 3 (range 13-20). Monofollicular development was observed in all patients that ovulated. One woman became pregnant and delivered a healthy baby. Conclusion: Bezafibrate may be effective for ovulation induction in CC-resistant PCOS patients with dyslipidemia.

• 出版日期2010